ALKEM LABS LTD FDA Approval ANDA 210519

ANDA 210519

ALKEM LABS LTD

FDA Drug Application

Application #210519

Documents

Letter2019-12-10

Application Sponsors

ANDA 210519ALKEM LABS LTD

Marketing Status

Prescription001
Prescription002
Prescription003

Application Products

001TABLET, FOR SUSPENSION;ORAL125MG0DEFERASIROXDEFERASIROX
002TABLET, FOR SUSPENSION;ORAL250MG0DEFERASIROXDEFERASIROX
003TABLET, FOR SUSPENSION;ORAL500MG0DEFERASIROXDEFERASIROX

FDA Submissions

UNKNOWN; ORIG1AP2019-11-20STANDARD

Submissions Property Types

ORIG1Null15

TE Codes

001PrescriptionAB
002PrescriptionAB
003PrescriptionAB

CDER Filings

ALKEM LABS LTD
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 210519
            [companyName] => ALKEM LABS LTD
            [docInserts] => ["",""]
            [products] => [{"drugName":"DEFERASIROX","activeIngredients":"DEFERASIROX","strength":"125MG","dosageForm":"TABLET, FOR SUSPENSION;ORAL","marketingStatus":"Prescription","te":"","rld":"No","rs":"No"},{"drugName":"DEFERASIROX","activeIngredients":"DEFERASIROX","strength":"250MG","dosageForm":"TABLET, FOR SUSPENSION;ORAL","marketingStatus":"Prescription","te":"","rld":"No","rs":"No"},{"drugName":"DEFERASIROX","activeIngredients":"DEFERASIROX","strength":"500MG","dosageForm":"TABLET, FOR SUSPENSION;ORAL","marketingStatus":"Prescription","te":"","rld":"No","rs":"No"}]
            [labels] => 
            [originalApprovals] => [{"actionDate":"11\/20\/2019","submission":"ORIG-1","actionType":"Approval","submissionClassification":"","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2019\\\/210519Orig1s000ltr.pdf\"}]","notes":"> Label is not available on this site."}]
            [supplements] => 
            [actionDate] => 2019-11-20
        )

)

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.